Vidarbha News

DelveInsight’s “Hemophilia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hemophilia, historical and forecasted epidemiology as well as the Hemophilia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Key Takeaways from the Hemophilia Market Research Report

• The increase in Hemophilia Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Hemophilia Market is anticipated to witness growth at a considerable CAGR.
• The leading Hemophilia Companies working in the market include ApcinteX, ASC Therapeutics, Ultragenix Pharmaceutical, BioMarin Pharmaceutical, CSL Behring, Freeline Therapeutics, Genentech, Inc., Novo Nordisk, Pfizer, Sanofi, Shire, Spark Therapeutics, Amarna therapeutics, Asklepios BioPharmaceutical, Bayer, Belief Biomed, Bioverativ, Catalyst Biosciences, Centessa Pharmaceuticals, Chameleon Biosciences, Chia Tai Tianqing Pharmaceutical Group, Expression Therapeutics, GC Pharma, GeneVentiv, Intellia tx, OPKO Health, Sangamo Therapeutics, Staidson Beijing BioPharmaceuticals, UBI Pharma, uniQure, and others.
• Promising Hemophilia Pipeline Therapies in the various stages of development include ASC618, Valoctocogene Roxaparvovec, Emicizumab, AAV5-hFIXco-Padua (AMT-061), BAX 888, SPK-8011, Fitusiran, BAY2599023, Verbrinacogene setparvovec, PF-07055480, NNC0365-3769 (Mim8) PPX, Nonacog beta pegol, SPK-8016, Concizumab (NN7415), Giroctocogene fitelparvovec (SB-525 or PF07055480), SerpinPC, and others.
• April 2024: ApcinteX Ltd- A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Hemophilia B With Inhibitors. The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) profile of prophylactic SerpinPC in participants with Hemophilia B with inhibitors, as part of the SerpinPC registrational program.
• April 2024: CSL Behring- Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies.
• April 2024: Regeneron Pharmaceuticals- A Prospective Study to Evaluate Disease Characteristics in Hemophilia B Participants Receiving Prophylaxis With Standard of Care FIX Replacement Therapy. This study is focused on males who have Hemophilia B and who need regular preventive treatment with factor IX protein (FIX) replacement therapy to prevent and also to control their bleeding events. The aim of the study is to gather at least 6 months of information on bleeding events for each individual participant while they continue to use their usual FIX replacement therapy.
• April 2024: Pfize- AN OPEN-LABEL STUDY IN PEDIATRIC (
• April 2024: Takeda- A Phase 3, Prospective, Multicenter, Open-label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (ADYNOVATE) Administered for Prophylaxis and Treatment of Bleeding in Chinese Previously Treated Patients With Severe Hemophilia A (FVIII <1%).

 

Discover which therapies are expected to grab the Hemophilia Market Share @ Hemophilia Market Outlook

 

Hemophilia Overview

Hemophilia is a genetic disorder that impairs the body’s ability to make blood clots, a process needed to stop bleeding. This condition is typically inherited and occurs most often in males. There are two main types of hemophilia — Hemophilia A and Hemophilia B.

 

Hemophilia Epidemiology Insights

The epidemiology section of Hemophilia offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

• Total Hemophilia Diagnosed Prevalent Pool
• Hemophilia Type-specific Prevalent Pool
• Hemophilia Severity-specific Prevalent Pool
• Hemophilia Inhibitor-specific Prevalent Pool
• Hemophilia Treated Prevalent Pool

 

Download the report to understand which factors are driving Hemophilia Epidemiology trends @ Hemophilia Epidemiological Insights

 

Hemophilia Drugs Market

The Hemophilia Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Hemophilia signaling in Hemophilia are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Hemophilia Treatment Market Landscape

The Hemophilia treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Hemophilia has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Hemophilia treatment guidelines, visit @ Hemophilia Treatment Market Landscape

 

Hemophilia Market Outlook

The report’s outlook on the Hemophilia market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Hemophilia therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Hemophilia drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Hemophilia market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Hemophilia Drugs Uptake

The drug chapter of the Hemophilia report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Hemophilia.

 

Major Hemophilia Companies

Several Hemophilia Companies working in the market include ApcinteX, ASC Therapeutics, Ultragenix Pharmaceutical, BioMarin Pharmaceutical, CSL Behring, Freeline Therapeutics, Genentech, Inc., Novo Nordisk, Pfizer, Sanofi, Shire, Spark Therapeutics, Amarna therapeutics, Asklepios BioPharmaceutical, Bayer, Belief Biomed, Bioverativ, Catalyst Biosciences, Centessa Pharmaceuticals, Chameleon Biosciences, Chia Tai Tianqing Pharmaceutical Group, Expression Therapeutics, GC Pharma, GeneVentiv, Intellia tx, OPKO Health, Sangamo Therapeutics, Staidson Beijing BioPharmaceuticals, UBI Pharma, uniQure, and others

 

Learn more about the FDA-approved drugs for Hemophilia @ Drugs for Hemophilia Treatment

 

Scope of the Hemophilia Market Research Report

• Coverage- 7MM
• Hemophilia Companies- ApcinteX, ASC Therapeutics, Ultragenix Pharmaceutical, BioMarin Pharmaceutical, CSL Behring, Freeline Therapeutics, Genentech, Inc., Novo Nordisk, Pfizer, Sanofi, Shire, Spark Therapeutics, Amarna therapeutics, Asklepios BioPharmaceutical, Bayer, Belief Biomed, Bioverativ, Catalyst Biosciences, Centessa Pharmaceuticals, Chameleon Biosciences, Chia Tai Tianqing Pharmaceutical Group, Expression Therapeutics, GC Pharma, GeneVentiv, Intellia tx, OPKO Health, Sangamo Therapeutics, Staidson Beijing BioPharmaceuticals, UBI Pharma, uniQure, and others
• Hemophilia Pipeline Therapies- ASC618, Valoctocogene Roxaparvovec, Emicizumab, AAV5-hFIXco-Padua (AMT-061), BAX 888, SPK-8011, Fitusiran, BAY2599023, Verbrinacogene setparvovec, PF-07055480, NNC0365-3769 (Mim8) PPX, Nonacog beta pegol, SPK-8016, Concizumab (NN7415), Giroctocogene fitelparvovec (SB-525 or PF07055480), SerpinPC, and others.
• Hemophilia Market Dynamics: Hemophilia Market Drivers and Barriers
• Hemophilia Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Hemophilia Drugs in development @ Hemophilia Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary of Hemophilia

3. Competitive Intelligence Analysis for Hemophilia

4. Hemophilia: Market Overview at a Glance

5. Hemophilia: Disease Background and Overview

6. Patient Journey

7. Hemophilia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Hemophilia Unmet Needs

10. Key Endpoints of Hemophilia Treatment

11. Hemophilia Marketed Products

12. Hemophilia Emerging Therapies

13. Hemophilia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Hemophilia

17. KOL Views

18. Hemophilia Market Drivers

19. Hemophilia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/